NCT00030446View on ClinicalTrials.gov

Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 10, 2002

Primary Completion Date

February 11, 2005

Study Completion Date

December 21, 2009

Conditions
Fallopian Tube CancerOvarian CancerPeritoneal Cavity Cancer
Interventions
DRUG

carboplatin

DRUG

erlotinib hydrochloride

Trial Locations (8)

T2N 4N2

Tom Baker Cancer Center - Calgary, Calgary

V1Y 5L3

British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna

V5Z 4E6

British Columbia Cancer Agency, Vancouver

B3H 2Y9

Queen Elizabeth II Health Science Centre, Halifax

L8V 5C2

Margaret and Charles Juravinski Cancer Centre, Hamilton

N6A 4L6

Cancer Care Ontario-London Regional Cancer Centre, London

M5G 2M9

Princess Margaret Hospital, Toronto

H4L 2M1

Hopital Notre- Dame du CHUM, Montreal

Sponsors
All Listed Sponsors
lead

NCIC Clinical Trials Group

NETWORK